{"name":"Chiasma, Inc.","slug":"chiasma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1106000,"revenueGrowth":0,"grossMargin":0,"rdSpend":26802000,"netIncome":-74779000,"cash":176338000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"octreotide capsules","genericName":"octreotide capsules","slug":"octreotide-capsules","indication":"Acromegaly","status":"phase_3"}]}],"pipeline":[{"name":"octreotide capsules","genericName":"octreotide capsules","slug":"octreotide-capsules","phase":"phase_3","mechanism":"Octreotide capsules mimic the natural hormone somatostatin to decrease production of growth hormone and other hormones.","indications":["Acromegaly","Gastrointestinal carcinoid syndrome","Hormone-secreting tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQU1JQMGpPZjRmSldFWUJxUUNocE05LXU4VV9PdVp5U2V3cDJVa1YtRXRIYjlhbWdHY3d5a0dCd1NUUnhOUGlnRGYzcWk5d3N2eEpzNzJya21WWFRvcHBjNG1ITk5OQjFxOHl0Y3l5TXV5dGhaUDlSaWtfQ09pSGlhdWFCMmJnUHFyRG1mVU5oSVdDQQ?oc=5","date":"2025-04-21","type":"pipeline","source":"Insightace Analytic","summary":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNN1dGTGtkdC1VZGthV2NsbXRiR3dnX1lHX0ZROW9MdGlQMHpmQm1fVXA0SzBSc0ZIZ184YWNPY2J2clI3Ynl6ejRKbTBDT2ZkYUhLUnhLTUZLZEkwUVdYZEV0QWJzVVVQdWllV1FYYUc0SzV1dExXSEc4dFNJRUFhdE1RNXRKeTFmR21XQ2NFdVFGM1gxcEthNjZPN0d3ZDFFbDRCYmxhZnFwT2dLd2tYUzl6YWFPSERJYTUxag?oc=5","date":"2023-10-27","type":"pipeline","source":"news.ecu.edu","summary":"Pharma leader and MBA alumnus delivers keynote at annual Business Leadership Conference - news.ecu.edu","headline":"Pharma leader and MBA alumnus delivers keynote at annual Business Leadership Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQeDdYeHNKbzdCM3NJaHh0b2VJcEhpRlVPRGZKbWxJd1lUOTNmVFExbkNhcmlqdl9YVmRXR1FUcGFUV3BlT3UtRDNGaXpITjBMa2dDb0I2Z0htZjY3NWRoNHRQM09kT09CaGhmY050VGJ3VHNGdkpCcS1BVGtjX1pCNQ?oc=5","date":"2023-06-22","type":"pipeline","source":"Contract Pharma","summary":"I-Mab Names Raj Kannan as CEO - Contract Pharma","headline":"I-Mab Names Raj Kannan as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcEF1UzBsLW9IdXdpN3NVdHE2eUlWeTAtSmNyRmk0WkI0WW5uWXZxTm1pcko4OEwwbjZ0VUdoTHMyZGdJakVtcVdlVk9sVmhOOHZ1aWtkc3N2NGFleVRwemg3OHBoWWVBc1lyeUU2TldIdHdJNDhKQl8tU3BpaDJDUk10c3ltdUQ2dVRBMlJiNlFlWExfXzIyR1RSTk5pbEdYU1puLUlETkxTM3c?oc=5","date":"2021-12-16","type":"pipeline","source":"citybiz","summary":"Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer - citybiz","headline":"Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxNaTI1ck5DUXBocldXaVNBbkpjLTd2NWpFNTc1UEw2YUJyLWw0cGJTQllSWGdKeGVWeGpJS3ladUVhNUZZNXhzQ1Bhb2FodjdacUZKc3VvYnc3M0xPX0VQNGhhT1pwYUxpYVBEYWhRQmprT2szblZWU19uaVQ3anplUHZZUzJaaE5FMi1rQXJyVUczSUdkSmFYSXR1SHVCNGtTWGZnWlQycUg1TEZzc0MzVkd6R2NkS2FmSEdpYmxwUUdTN1VvMTE4YVpyaXVKU0FZZEZkbllEcjhvMW45NzlhTGl2NXlqdnM5WmxQVy1GSXFUel9VUENjNnhxY3pwQlI1MGlhRVZTVThqVFh1QVRkcS1aNHlJbHVHRVVjMnl3?oc=5","date":"2021-08-05","type":"pipeline","source":"GlobeNewswire","summary":"Amryt Successfully Completes Acquisition of Chiasma, Inc., - GlobeNewswire","headline":"Amryt Successfully Completes Acquisition of Chiasma, Inc.,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9WVzFjaTZGbmpIQ2R5X1NDeG54Zkt4NlRjLXlFcmFaNW01RnBDeUJiLVRjTURLSlA0ME8xUWZIMk5JejRGbUZWWGlhSDFreXEzYzBxek9MWmxVNXZIZFFvTEVOSDhEZWRfT0ZLa1p3?oc=5","date":"2021-05-20","type":"pipeline","source":"Anton Health","summary":"Hospital Specialty Pharmacy Network Nails Another LDD - Anton Health","headline":"Hospital Specialty Pharmacy Network Nails Another LDD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxONzFUVzQ3ZVdNYzJveXVwbDRmR2ZjNFA5MlR6bXFtTEs5WkdxQ0UtZ3ZrRFFOYlZHS01DWlNvT3hEallsbXczck00MDBIYmZiaTlwSHN2OXppTm1BWUlvUmd3Y01FTkZUc1BTZmd2YnpUOGxURXNDZGl4Y3NaeXhGdEZaVElLZXpQRU85bXQybjAtQWtXNVM2NEdnUEtNOExNc0djdGFySUdiZmFUM3d3Rw?oc=5","date":"2021-05-06","type":"pipeline","source":"The Times","summary":"Rare disease rivals Amryt Pharma and Chiasma to merge - The Times","headline":"Rare disease rivals Amryt Pharma and Chiasma to merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPLWhCMVZxTVFNamRmbEdVdVUwQnE2NlpOM2paNXhPSXZVUlZselVnSVVma2hHUG9lYndFeGpWV3Z6OFJpU0Jma3BoY0VDdTRhMFJ3Unk2SWU1R29UNG56cnh2ZEJDcDh6akJXQVZhOXRPeFdkU08tZ3U0MXQ4VUkyRDc4MzgzTlpXR0ZkTGJ1RElhV2NSamRhcVBnN2tYSHJKYUowWV9IYWVlNTlWbjV3dG5BNXZuQ0RhMGdIWGVMWlNlZzhxeGR6aGhzS0UzM0ZIaHdOb0d3bGU2R0g0c1BtZWNpbUx4OTdScVV4bk9WdGtFelRMYzNzVG9nTmFiNUFfR21hYXZn?oc=5","date":"2021-05-05","type":"deal","source":"GlobeNewswire","summary":"Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases - GlobeNewswire","headline":"Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1GWk4tMTBZZVpzMTJvNjFXcTdYWTE3U3pyWUJUZk12ZnhqR0hFX1JXcVVoLTVMaEJxQk5aelo5YVNGVmp4RnBKb2dCYjlxZnMtd0xGX2JkYS1KT29lS0tiME0tbw?oc=5","date":"2019-06-15","type":"pipeline","source":"Market.us","summary":"Acromegaly Treatment Market Size, Share, Price | CAGR of 7.7% - Market.us","headline":"Acromegaly Treatment Market Size, Share, Price | CAGR of 7.7%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNldLRTYxR3lHdXNqMEVFRkRPaldLcllrbHJtLTZWZURNZzZ6dzhkOHBrUXBOa1Q3ZS1OdEg0ekRJRzRoZ3VXY3RuN2VMMko5SzFGUTZaMm9MTnVYNVozVnZSdkNSWkdrQ0pvazJHUFhMRDVCUFk3TUU1X29wOW1EU0Z5MGo4eEhaMFJfR1UtUjN5UUtxQWJwb3NxTkJUOE0tMlVITU5KNWM?oc=5","date":"2016-12-28","type":"regulatory","source":"Fierce Pharma","summary":"The FDA's promo police slap four more pharmas in year-end enforcement spree - Fierce Pharma","headline":"The FDA's promo police slap four more pharmas in year-end enforcement spree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOMEdVbnFuV3hGUVYwUi1LTmxMVDlXMmRXN243VmhPeWo5cHV6eVc4Z01EVGRuOElBQ0FFY1dncVFzdVl6UXZBc25ZdlI3eUlvajM4VlhsbFNxSnlqNGZpWFVkWVFrV0VGOWtFejhCTW1neTBOdldEUEFqd0lMYVlGTUx1bXo3Rl9oWUY4ek1HVlZ4bk51MWpQc1dpWFkyZkhqNjB4eVNPVGZvdmpTNkpPV3RBVnFWX0RyVmZBbmpabzZNQ3A0NDRHQmxhU3VTT1dJR1ZMb3NSdw?oc=5","date":"2015-06-15","type":"regulatory","source":"PR Newswire","summary":"Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly - PR Newswire","headline":"Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOLUZoWjdHX0dFY19iTzMzYkt1a09lc3BSY2RVZmo1REE3TktXQ1A2T3loVzQtQjVyMkQ3alcwLU5ZaUp4SE5pWlEzMnpYZ3k2ekJnRmRJRHp1SXB3MGdkbmh3cS1wSnYxejBRNWpma3RIdHhJbkZpSkE3VUVWWlhBMWl2cDNNRFJzWF9vLTFfeTN0VjdaR0FaTU1XOGhid0dfejA3Wk1n?oc=5","date":"2014-08-14","type":"deal","source":"BioPharma Dive","summary":"Roche backs out of $600 million development deal with Chiasma - BioPharma Dive","headline":"Roche backs out of $600 million development deal with Chiasma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1106000,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":1106000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26802000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74779000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":176338000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}